Table of Contents

Research Articles: Therapeutics, Targets, and Development

• Research Articles: Therapeutics, Targets, and Development

  Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

  Swee Y. Sharp, Chrisostomos Prodromou, Kathy Boxall, Marissa V. Powers, Joanna L. Holmes, Gary Box, Thomas P. Matthews, Kwai-Ming J. Cheung, Andrew Kalusa, Karen James, Angela Hayes, Anthea Hardcastle, Brian Dymock, Paul A. Brough, Xavier Barril, Julie E. Cansfield, Lisa Wright, Allan Surgenor, Nicolas Foloppe, Roderick E. Hubbard, Wynne Aherne, Laurence Pearl, Keith Jones, Edward McDonald, Florence Raynaud, Sue Eccles, Martin Drysdale and Paul Workman

  Mol Cancer Ther April 1 2007 6 (4) 1198-1211; DOI:10.1158/1535-7163.MCT-07-0149

  
  
• Research Articles: Therapeutics, Targets, and Development

  MAP-ing glioma invasion: Mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival

  Tim Demuth, Linsey B. Reavie, Jessica L. Rennert, Mitsutoshi Nakada, Satoko Nakada, Dominique B. Hoelzinger, Christian E. Beaudry, Amanda N. Henrichs, Eric M. Anderson and Michael E. Berens

  Mol Cancer Ther April 1 2007 6 (4) 1212-1222; DOI:10.1158/1535-7163.MCT-06-0711

  
  
• Research Articles: Therapeutics, Targets, and Development

  Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens

  Lorenzo Daniele, Luigia Macrì, Marina Schena, Diego Dongiovanni, Lisa Bonello, Enrico Armando, Libero Ciuffreda, Oscar Bertetto, Gianni Bussolati and Anna Sapino

  Mol Cancer Ther April 1 2007 6 (4) 1223-1229; DOI:10.1158/1535-7163.MCT-06-0719

  
  
• Research Articles: Therapeutics, Targets, and Development

  Use of fluorescent labeled anti–epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts

  Eben L. Rosenthal, Brian D. Kulbersh, Teresa King, Tandra R. Chaudhuri and Kurt R. Zinn

  Mol Cancer Ther April 1 2007 6 (4) 1230-1238; DOI:10.1158/1535-7163.MCT-06-0741

  
  
• Research Articles: Therapeutics, Targets, and Development

  H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation

  Brett Ewald, Deepa Sampath and William Plunkett

  Mol Cancer Ther April 1 2007 6 (4) 1239-1248; DOI:10.1158/1535-7163.MCT-06-0633

  
  
• Research Articles: Therapeutics, Targets, and Development

  Activation of a novel ataxia-telangiectasia mutated and Rad3 related/checkpoint kinase 1–dependent prometaphase checkpoint in cancer cells by diallyl trisulfide, a promising cancer chemopreventive constituent of processed garlic

  Anna Herman-Antosiewicz, Silvia D. Stan, Eun-Ryeong Hahm, Dong Xiao and Shivendra V. Singh

  Mol Cancer Ther April 1 2007 6 (4) 1249-1261; DOI:10.1158/1535-7163.MCT-06-0477

  
  
• Research Articles: Therapeutics, Targets, and Development

  Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib

  Peter Pyrko, Adel Kardosh, Yen-Ting Liu, Nathaniel Soriano, Wenyong Xiong, Robert H. Chow, Jasim Uddin, Nicos A. Petasis, Austin K. Mircheff, Robert A. Farley, Stan G. Louie, Thomas C. Chen and Axel H. Schönthal

  Mol Cancer Ther April 1 2007 6 (4) 1262-1275; DOI:10.1158/1535-7163.MCT-06-0629

  
  
• Research Articles: Therapeutics, Targets, and Development

  Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer

  Lan Li, Bilal Ahmed, Kapil Mehta and Razelle Kurzrock

  Mol Cancer Ther April 1 2007 6 (4) 1276-1282; DOI:10.1158/1535-7163.MCT-06-0556

  
  
• Research Articles: Therapeutics, Targets, and Development

  Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice

  Mark Katzenellenbogen, Lina Mizrahi, Orit Pappo, Naama Klopstock, Devorah Olam, Hila Barash, Eytan Domany, Eithan Galun and Daniel Goldenberg

  Mol Cancer Ther April 1 2007 6 (4) 1283-1291; DOI:10.1158/1535-7163.MCT-06-0420

  
  
• Research Articles: Therapeutics, Targets, and Development

  Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells

  Mercedes Salido, Juan L. Gonzalez and Jose Vilches

  Mol Cancer Ther April 1 2007 6 (4) 1292-1299; DOI:10.1158/1535-7163.MCT-06-0681

  
  
• Research Articles: Therapeutics, Targets, and Development

  The RET oncogene is a critical component of transcriptional programs associated with retinoic acid–induced differentiation in neuroblastoma

  Orit Oppenheimer, Nai-Kong Cheung and William L. Gerald

  Mol Cancer Ther April 1 2007 6 (4) 1300-1309; DOI:10.1158/1535-7163.MCT-06-0587

  
  
• Research Articles: Therapeutics, Targets, and Development

  Levels of p27^kip1 determine Aplidin sensitivity

  Victoria Moneo, Beatriz G. Serelde, Juan F.M. Leal, Carmen Blanco-Aparicio, Ramon Diaz-Uriarte, Miguel Aracil, Juan C. Tercero, José Jimeno and Amancio Carnero

  Mol Cancer Ther April 1 2007 6 (4) 1310-1316; DOI:10.1158/1535-7163.MCT-06-0729

  
  
• Research Articles: Therapeutics, Targets, and Development

  Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function

  Katherine Schafer-Hales, Jon Iaconelli, James P. Snyder, Andrew Prussia, James H. Nettles, Adel El-Naggar, Fadlo R. Khuri, Paraskevi Giannakakou and Adam I. Marcus

  Mol Cancer Ther April 1 2007 6 (4) 1317-1328; DOI:10.1158/1535-7163.MCT-06-0703

  
  
• Research Articles: Therapeutics, Targets, and Development

  Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer

  Dorit Nahari, Ronit Satchi-Fainaro, Ming Chen, Ian Mitchell, Laurie B. Task, Zijuan Liu, Jason Kihneman, Allison B. Carroll, Lance S. Terada and Fiemu E. Nwariaku

  Mol Cancer Ther April 1 2007 6 (4) 1329-1337; DOI:10.1158/1535-7163.MCT-06-0554

  
  
• Research Articles: Therapeutics, Targets, and Development

  Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH₂-terminal kinase–mediated p53 phosphorylation and stabilization

  Ranxin Shi, Qing Huang, Xinqiang Zhu, Yeong-Bing Ong, Bin Zhao, Jia Lu, Choon-Nam Ong and Han-Ming Shen

  Mol Cancer Ther April 1 2007 6 (4) 1338-1347; DOI:10.1158/1535-7163.MCT-06-0638

  
  
• Research Articles: Therapeutics, Targets, and Development

  Identification of a novel inhibitor of urokinase-type plasminogen activator

  Ming Zhu, Vijay M. Gokhale, Lajos Szabo, Ruben M. Munoz, Hyounggee Baek, Sridevi Bashyam, Laurence H. Hurley, Daniel D. Von Hoff and Haiyong Han

  Mol Cancer Ther April 1 2007 6 (4) 1348-1356; DOI:10.1158/1535-7163.MCT-06-0520

  
  
• Research Articles: Therapeutics, Targets, and Development

  Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo

  Ta-Jen Liu, Tiffany LaFortune, Toshiyuki Honda, Osamu Ohmori, Shinji Hatakeyama, Thomas Meyer, Dowdy Jackson, John de Groot and W.K. Alfred Yung

  Mol Cancer Ther April 1 2007 6 (4) 1357-1367; DOI:10.1158/1535-7163.MCT-06-0476

  
  
• Research Articles: Therapeutics, Targets, and Development

  S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11–induced apoptosis of prostate cancer cells

  Subrata Ray, Sunitha Shyam, Gail C. Fraizer and Alexandru Almasan

  Mol Cancer Ther April 1 2007 6 (4) 1368-1378; DOI:10.1158/1535-7163.MCT-05-0414

  
  
• Research Articles: Therapeutics, Targets, and Development

  Clofibric acid, a peroxisome proliferator–activated receptor α ligand, inhibits growth of human ovarian cancer

  Yoshihito Yokoyama, Bing Xin, Tatsuhiko Shigeto, Mika Umemoto, Akiko Kasai-Sakamoto, Masayuki Futagami, Shigeki Tsuchida, Fahd Al-Mulla and Hideki Mizunuma

  Mol Cancer Ther April 1 2007 6 (4) 1379-1386; DOI:10.1158/1535-7163.MCT-06-0722

  
  
• Research Articles: Therapeutics, Targets, and Development

  Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1

  Stavroula Baritaki, Sara Huerta-Yepez, Toshiyuki Sakai, Demetrios A. Spandidos and Benjamin Bonavida

  Mol Cancer Ther April 1 2007 6 (4) 1387-1399; DOI:10.1158/1535-7163.MCT-06-0521

  
  
• Research Articles: Therapeutics, Targets, and Development

  Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells

  Sangkil Nam, Ann Williams, Adina Vultur, Alan List, Kapil Bhalla, David Smith, Francis Y. Lee and Richard Jove

  Mol Cancer Ther April 1 2007 6 (4) 1400-1405; DOI:10.1158/1535-7163.MCT-06-0446

  
  
• Research Articles: Therapeutics, Targets, and Development

  Loss of ataxia telangiectasia mutated– and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival

  Deborah Wilsker and Fred Bunz

  Mol Cancer Ther April 1 2007 6 (4) 1406-1413; DOI:10.1158/1535-7163.MCT-06-0679

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer

  Qing Zhang, Neil E. Bhola, Vivian Wai Yan Lui, Doris R. Siwak, Sufi M. Thomas, Christopher T. Gubish, Jill M. Siegfried, Gordon B. Mills, Dong Shin and Jennifer Rubin Grandis

  Mol Cancer Ther April 1 2007 6 (4) 1414-1424; DOI:10.1158/1535-7163.MCT-06-0678

  
  
• Research Articles: Therapeutics, Targets, and Development

  Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells

  Maxy De los Santos, Alberto Zambrano and Ana Aranda

  Mol Cancer Ther April 1 2007 6 (4) 1425-1432; DOI:10.1158/1535-7163.MCT-06-0623

  
  
• Research Articles: Therapeutics, Targets, and Development

  1α,25-dihydroxyvitamin D₃ (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells

  Moshe Ben-Shoshan, Sharon Amir, Duyen T. Dang, Long H. Dang, Yosef Weisman and Nicola J. Mabjeesh

  Mol Cancer Ther April 1 2007 6 (4) 1433-1439; DOI:10.1158/1535-7163.MCT-06-0677

  
  
• Research Articles: Therapeutics, Targets, and Development

  Inhibition of nuclear factor-κB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation

  Yasuhisa Oida, Began Gopalan, Ryo Miyahara, Cynthia D. Branch, Paul Chiao, Sunil Chada and Rajagopal Ramesh

  Mol Cancer Ther April 1 2007 6 (4) 1440-1449; DOI:10.1158/1535-7163.MCT-06-0374

  
  
• Research Articles: Therapeutics, Targets, and Development

  Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate

  Suzanne M. Cutts, Lonnie P. Swift, Vinochani Pillay, Robert A. Forrest, Abraham Nudelman, Ada Rephaeli and Don R. Phillips

  Mol Cancer Ther April 1 2007 6 (4) 1450-1459; DOI:10.1158/1535-7163.MCT-06-0551

  
  
• Research Articles: Therapeutics, Targets, and Development

  Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met–expressing tumors

  Todd D. Francone, Ron G. Landmann, Chin-Tung Chen, Mark Y. Sun, Eleanor J. Kuntz, Zhaoshi Zeng, Ronald P. Dematteo, Philip B. Paty and Martin R. Weiser

  Mol Cancer Ther April 1 2007 6 (4) 1460-1466; DOI:10.1158/1535-7163.MCT-06-0466

  
  
• Research Articles: Therapeutics, Targets, and Development

  Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acid–induced cytotoxicity

  Wei-Qun Ding and Stuart E. Lind

  Mol Cancer Ther April 1 2007 6 (4) 1467-1474; DOI:10.1158/1535-7163.MCT-06-0608